Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: Ben Geh who wrote (735)	9/10/1999 8:54:00 AM
From: opalapril	Read Replies (1) \| Respond to of 849

Excuse, please. Stopped by after seeing the news but I am really dumb. Can someone please enlighten me? 1. Blood tests for cancer screening are done routinely by physicians and have been for some time. So what is it they are looking for and how does NMPS's protein marker test differ? 2. The press release mentioned a test group of 20 known breast cancer victims and 20 thought to be free of breast cancer. No informationn was given about how early/late the first 20 had their cancer diagnosed or by what means. I understand the NMPS test is designed for early detection, so how "early" was the test used viz a viz the first 20 known victims? 3. Does anyone happen to know how widespread the use of NMPS' bladder cancer blood test is in U.S. clinics and hospitals? Revenues from that? Thanks for your tolerance and any answers.